AI Article Synopsis
- Cancer cells rely on nucleotides for growth, and current treatments using antimetabolites target nucleotide metabolism, but issues like resistance and toxicity can limit their effectiveness.
- Researchers are exploring the pyrimidine de novo synthesis pathway, vital for cancer cell proliferation, which has not seen much success in treatment applications yet.
- The study outlines a method for creating a subcutaneous tumor model lacking this synthesis pathway and suggests using MALDI imaging to analyze how these tumors respond metabolically to this blockade.
Article Abstract
Cancer cells depend on nucleotides for proliferation. Inhibition of nucleotide metabolism by antimetabolites is a well-established anticancer therapy. However, resistance and toxicity to antimetabolite treatments reduce their effectiveness. Here, we focus on the pyrimidine de novo synthesis pathway, which is crucial for cancer cell proliferation, yet its pharmacological targeting in cancer has been without much clinical success so far. Hence, it is important to understand how cancer cells cope with the insufficiency of this pathway. Here, we describe a procedure to prepare subcutaneous tumor model deficient in de novo pyrimidine synthesis. For examination of metabolic responses to de novo synthesis blockade in tumors, we propose application of MALDI imaging that allows spatially resolved examination of metabolic responses to de novo synthesis blockade in tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-1-0716-3247-5_22 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!